# Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

> **NCT01942837** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 67 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT01942837
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-13
- **Primary completion:** 2021-12
- **Final completion:** 2022-09-30
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2022-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01942837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01942837, "Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01942837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*